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ABSTRACT 
The role of the plasma level of homocysteine (Hcy), as a primary outcome, and the effect 
of silent cerebrovascular lesions and genetic variants related to Hcy metabolism, as 
secondary outcomes, in the cognitive decline and dementia in Parkinson’s disease (PD) 
were studied. This case-control study focused on 89 PD patients of minimum 10 years of 
evolution and older than 60 y.o., who were neuropsychologically classified either as 
cognitively normal (n= 37), having mild cognitive impairment (Petersen criteria) (n=22) 
or suffering from dementia (DSM-IV) (n=30), compared with cognitively normal age-
matched control subjects (n=30). Plasma levels of Hcy, Vitamins B12 and B6, folic acid, 
polymorphisms in genes related to Hcy metabolism (MTHFR, MTR, MTRR, CBS) and 
silent cerebrovascular events were analysed.  Plasma levels of Hcy were increased in PD 
patients (p=0.0001). There were no differences between the groups of patients. The brain 
vascular burden was similar among PD groups. There was no association between 
polymorphisms in the studied genes and the Hcy plasma levels or cognitive status in PD 
patients. We found no evidence for a direct relationship between Hcy plasma levels and 
cognitive impairment and dementia in PD. No indirect effect through cerebrovascular 
disease or genetic background was either found. 
 
Key words: Homocysteine, Parkinson’s disease, dementia, mild cognitive impairment, 
genetics, white matter hyperintensities 
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INTRODUCTION 
Dementia is a frequent manifestations of advanced Parkinson´s disease (PD) 1, 2. 
Advanced age, longer duration of disease and greater severity  are associated with 
dementia in PD1. Elevated plasma homocysteine (Hcy) levels represent a risk factor for 
cognitive decline and dementia in the general population3 and have been associated with 
mild cognitive impairment (MCI)4, Alzheimer's disease (AD)4, 5, vascular dementia6 and 
depression7. In patients with PD, levodopa treatment leads to increased Hcy plasma 
levels,8-11. Hcy is regulated by several metabolic pathways (Figure 1) and may be 
determined by genetic and dietary factors. Genetic polymorphisms in genes encoding 
enzymes involved in Hcy metabolism could be partly responsible for the 
hyperhomocysteinemia observed in some PD patients. For instance, remethylation of 
Hcy may be more or less efficient depending on the activity of the enzyme MTHFR 
(5,10-Methylen-tetrahydrofolate reductase), which is determined by different genotypes 
12. The T/T variant of the genotype C677T of the MTHFR reduces its enzymatic activity, 
leading to higher levels of Hcy in patients treated with levodopa12-14. However, this 
association has not been found in other studies15. All of the above leads to postulate a 
role for increased Hcy levels as a risk factor in the development of dementia in PD. 
Indeed, several open trials have been performed to reduce Hcy levels in PD patients 
using vitamin B12, folate supplements or treatment with catechol-o-methyl transferase 
(COMT) inhibitors16-20. This leads to the somewhat irregular situation where a 
therapeutic approach is tested for an association (i.e. high Hcy levels and dementia in 
PD) which has not been proven21.  Current information is limited to a few studies10, 22-24 
which have provided contradictory results.  We analyzed a large group of PD patients to 
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extensively assess the possible correlation between Hcy plasma levels and the 
development of dementia.  
 
METHODS 
The Ethics Committee for Medical Research approved the study. All patients and 
controls provided written informed consent. For patients with dementia, this was 
obtained from a relative.  PD patients diagnosed according to the UK Brain Bank 
criteria25 were recruited from our movement disorders clinic . Patients were older than 60 
y.o. and had disease duration of 10 years or longer. Patients with other brain disorders, 
vascular or severe systemic disease, major psychiatric illness, previous cerebral surgery, 
or receiving anticonvulsants, vitamin B, folate supplements or COMT inhibitors were 
excluded. The Hoehn and Yahr scale and the Unified Parkinson´s Disease Rating Scale 
motor section (UPDRS-III) were used to evaluate disease severity.  Patients were 
classified as being cognitively normal (PD-CN), with mild-cognitive impairment (PD-
MCI) and demented (PD-D). MCI was  defined according to Petersen et al´s criteria26  
which includes memory complaint, normal activities of daily living, normal general 
cognitive function, abnormal memory for age, and absence of dementia. The DSM-IV 
criteria were applied for diagnosis dementia. Patients exhibited multiple cognitive 
deficits (table 2) and impairment of daily life activities.  Healthy controls were recruited 
among members of the Association of Blood Donors of Navarra (Spain). Cases with 
history of any neurological, psychiatric or major medical illness, with scores below 
normal in the neuropsychological assessment or with abnormalities in the MRI were 
ruled out.   
 
Rodriguez-Oroz 
6
The primary aim of this study was to determine the relationship between Hcy plasma 
levels and cognitive decline in advanced PD patients. Secondary objectives were the role 
of genetic factors related to Hcy metabolism and of silent vascular events in the cognitive 
decline of PD patients and their possible association with Hcy levels. The relationship 
between depression and Hcy and the role of factors such as vitamins Bs and folate 
plasma levels were also investigated. 
 Neuropsychological evaluations 
Global cognitive function was evaluated with the Mini Mental State of Folstein 
(MMSE)27 and the Blessed cognitive scale (BDS)28. Activities of daily living were 
evaluated with the Interview for Deterioration in Daily Living in Dementia scale 
(IDDD)29. Depression was rated using the Yesavage Geriatric Depression Rating Scale 
(GDS)30. The different cognitive domains were evaluated by the following tests:  verbal 
episodic memory (Free and Cue Selective Reminding test of Buschke31 and Cerad word 
list32); visual episodic memory (copy and delayed recall of two simple figures 
(Massachusetts General Hospital, Boston)); language (Boston naming test)33; attention 
and executive functions ( Raven Progressive matrices34, semantic (animals) and phonetic 
(words starting with “p”) verbal fluency35, Trail Making Test parts A and  B36, the Stroop 
test and digit span forward and backwards37). All tests were blindly applied by the same 
person in each center to control subjects and patients while under treatment, and were 
used alongside the diagnostic criteria described above to determine the cognitive status.  
Biochemistry 
All blood samples were obtained by antecubital venopuncture under fasting conditions 
and 4-6 hours after the first morning levodopa dose in PD patients.  Plasma levels of 
Hcy, Vitamin B12 and folate were determined using a solid phase competitive 
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chemiluminescent enzyme immunoassay (INMUNOLITE 2500). Vitamin B6 was 
determined by radioisotopic assay (BUHLMANN laboratories Ag, Switzerland 
ALLSCHWIL). 
Genetic study 
Seven polymorphisms in genes involved in Hcy metabolism were typed using either 
restriction fragment length polymorphism (RFLP) assays or allele specific amplification 
with the primers and conditions available upon request. The polymorphisms included in 
this study were rs1801133 (c.C677T, p.A222V) and rs1801131 (c.A1298C, p.E429A) in 
MTHFR (accession numbers: NM_005957, NP_005948), rs1805087 (c.A2756G, 
p.D919G) in methionine synthase (MTR) (accession numbers: NM_000254, 
NP_000245), rs1801394 (c.A66G, p.I22M) in methionine synthase reductase (MTRR) 
(accession numbers: NM_002454, NP_002445) and c.844ins68, rs5742905 (c.T833C, 
p.I278T) and rs11700812 (c.G919A, p.R369H) in Cystathionine β-synthase (CBS) 
(accession numbers: NM_000071, NP_000062).  
Magnetic Resonance Imaging (MRI)  
All patients had an image study to exclude other causes of cognitive impairment.  
Because of practical reasons, in 18 cases only a CT brain scan could be performed. A 3-
D structural MRI (1.5 T Magneton SP (Siemens Erlangen, Gr) was performed in the rest 
of patients and controls using a T1-weighted MPRAGE sequence, (TR/TE/TI/NEX 
1900/3.93/1100/1, flip angle 15º), matrix size 256  192, yielding 144 coronal slices and 
a slice thickness of 1.5 mm with in-plane resolution of 0.9765625 0.9765625 mm. 
FLAIR and T2-weighted sequences were also obtained. All MRI studies were undertaken 
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the same week that the neuropsychological and physical evaluation by the same 
radiologist who was not aware of the cognitive status of the patients and the Hcy levels.  
Brain vascular burden (white matter hyperintensities-WMH) was analyzed on FLAIR and 
T2 weighted MRI sequences. WMH were defined as hyperintense lesions on both 
sequences images. Only deep lesions of more than 5mm were counted. Caps and 
periventricular lesions less than 10 mm thick were not taken into consideration. WMH 
were semi-quantified using the ARWMC (age related WMH) scale of the European Task 
Force for the study of leukoaraiosis (Wahlund scale) 38. This scale was blindly applied 
by 2 neurologists.  
 
 Statistics 
The normal distribution of all variables was assessed using the Kolmogorov-Smirnov test. 
Distribution of the variables among the different groups (table 1) was assessed using 
Kruskal Wallis, ANOVA and mid-p test depending on the distribution and characteristics 
of the variable. A logarithmic transformation was applied as needed for the regression 
models. For the primary end point, a multinomial logistic regression was used for analysis. 
Secondary end points were assessed by linear multiple regression. Post-hoc Bonferroni’s 
correction for multiple comparisons was applied. The statistics package SPSS 15.0 (SPSS 
Inc. Chicago, Illinois) and WinPepi 1.66 (PEPI-for-Windows) was used. 
 
RESULTS 
 Eighty-nine patients with PD classified as PD-CN (n=37), PD-MCI (n= 22) and PD-D 
(n=30) and 30 controls were studied. 
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The general characteristics of the groups are shown in table 1. PD-D patients were older 
than all other groups and had a higher depression score (table 1). Patient groups were 
comparable regarding years of evolution, severity of the disease and daily levodopa dose. 
All patients were receiving treatment with levodopa and 53 received additional treatment 
with a dopamine agonist (25 pramipexol, 14 ropinirol, 10 cabergoline, 4 pergolide). Sex 
distribution and level of education were similar among groups. 
Hcy plasma levels and biochemical data   
A linear multiple regression model for possible variables influencing Hcy levels was 
undertaken. Sex, disease duration and levodopa daily dose were not associated with Hcy 
plasma levels. Age, was positively associated with Hcy plasma levels. Acid folic, Vit 
B12 and Vit B6 were inversely associated with the plasma concentration of Hcy (global 
model: p=0.00015, adjusted R square =0.305). Plasma levels of vitamins B12 and B6 and 
folate did not differ among patient groups.  
Plasmatic Hcy levels were higher (table 1) in PD patients than in controls (p= 0.0001).  
Hcy levels did not predict cognitive status (p=0.403) in a multinomial logistic regression 
of PD patients adjusting for variables influencing Hcy plasma levels and cognitive decline 
(age, Vit B12, Vit B6 and folic acid).  Results were similar when pooling together PD 
patients with any degree of cognitive impairment (i.e. PD-MCI plus PD-D). No 
correlation was found between Hcy plasma levels and performance on 
neuropsychological tests (table 2).  
Genetic Study 
 The control population was in Hardy-Weinberg equilibrium for all polymorphisms 
analyzed except for the MTRR-A66G. For this reason, this SNP was excluded from the 
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analysis. All three polymorphisms in the CBS gene were in complete linkage 
disequilibrium, and therefore only data for the c.844ins68 polymorphism is shown. 
Due to the low number of individuals homozygous for the mutant genotype in some 
polymorphisms, the analysis was performed grouping together those genotypes carrying 
at least one mutant, i.e. less frequent allele (TT plus CT for the c.C677T MTHFR; GG 
plus AG for the  MTR c.A2756G; ins+/ins+ plus ins+/ins- for the c.844ins68 CBS). 
Linear multiple regression analysis for variables influencing Hcy concentration  (age, Vit 
B12, Vit B6 and folic acid) was applied to assess whether or not these polymorphisms 
influenced  Hcy plasma levels. This revealed that Hcy levels are independent of the 
genetic variants (table 3). Moreover, we found no relation between the genetic variants 
and Hcy plasma levels in the control group. 
A multinomial logistic regression model adjusting for age was applied to assess the effect 
of the genetic variants in the cognitive status of PD patients.  There was no association 
between any polymorphisms and the cognitive status even when pooling together all 
patients with some degree of cognitive impairment (i.e PD-MCI plus PDD patients) 
(table 4).  None of the studied polymorphisms was associated with increased risk of PD.   
 White matter changes in MRI 
In 3 patients the Flair sequences of the MRI were not suitable to evaluate the Whalund 
scale, so sixty-eight patients were available for analysis. The scores on the Wahlund 
scale were 1.32 ± 1.96 in PD-CN; 1.57±2.14 in PD-MCI and 2.10±2.19 in PD-D patients. 
Adjusting for age, there were no differences among the groups of patients (p=0.958). 
Interestingly, age and Hcy plasmatic levels were independently associated with the 
Wahlund scores, but there was no association when both variables were included in a 
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multinomial logistical regression model. This could be due to the fact that silent vascular 
events and Hcy plasmatic levels increase with age.  
Depression 
Patients with PD-D (p<0.001) and with PD-MCI (p=0.007) were more depressed than 
PD-CN patients (GDS= 11.814.30 in PD-D; 10.60  4.9 in PD-MCI and 5.85  3.70 in 
PD-CN). There was no difference between PD-CN patients and controls (GDS= 4.5 
3.7). No correlation between Hcy plasma levels and depression (r=0.154, p=0.233) was 
found.  None of the variants of the polymorphisms studied was associated with 
depression. 
 
DISCUSSION 
Hcy plasma levels and dementia 
We found no relationship between Hcy plasma levels and cognitive impairment in 
patients with PD. Our pilot study included an extensive analysis of a fairly large cohort 
of PD patients and a detailed neuropsychological evaluation that allowed appropriate 
classification according to the cognitive status. After adjusting for factors influencing 
Hcy plasma levels and cognitive decline in a multinomial logistic regression model, we 
found that Hcy plasma levels did not predict the cognitive status of PD patients. 
Although a ceiling effect in all PD groups due to the effect of levodopa on Hcy may be 
partially responsible for this negative finding, we failed to detect any association between 
levels of Hcy and cognitive status or neuropsychological performance. Previous studies 
investigating this subject yielded contradictory results. Higher Hcy plasma levels in 
patients with cognitive decline than in non-demented patients39 were reported in a 
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retrospective study conducted in a reduced number of patients in whom the MMSE was 
the only test used for evaluation.  Religa et al10 found a correlation between high Hcy 
plasma levels and low MMSE scores. However, the PD group had low vitamin B12 
levels, which might be a confounding factor affecting these results.  High levels of Hcy 
have also been associated with poorer performance in frontal and memory tests22 in PD . 
On the other hand, one prospective study in early PD patients showed no difference in 
motor, mood and cognitive deterioration between patients with and without high Hcy 
levels after levodopa treatment was initiated,23 suggesting that disease progression is not 
associated with Hcy plasma concentration. Similar negative findings were reported in a 
cross-sectional study of 72 PD patients in whom there was no association between Hcy 
and depression, cognitive performance and psychosis24. A recent study of demented PD 
patients showed a similar degree of cognitive impairment in patients with low and high 
Hcy levels 40. In our study, patients were evaluated thoroughly from a 
neuropsychological point of view and the patient population was sufficiently old and had 
suffered PD for long enough to be at risk of developing dementia1. This makes it very 
unlikely that our negative findings could be explained by a population bias.  Moreover, 
our statistical analysis was corrected for age and disease duration, and no significant 
correlation was found. We also took care to differentiate PD patients with MCI and 
dementia under the hypothesis that MCI could be the earliest phase of cognitive decline 
in PD 41, so our patient population was more accurately classified than in previous 
studies. While the appropriateness of Petersen’s criteria to evaluate MCI in PD may be 
questioned42, the fact is that by analyzing (separately or together) PD patients with 
dementia and with MCI, we should have increased the sensitivity to detect any possible 
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association between plasma Hcy levels and cognitive impairment. Moreover, we found 
no correlation between the scores on the neuropsychological tests and Hcy plasma levels.   
We also assessed the role of ischemia as a factor associated with dementia. 
Hyperhomocysteinemia is a risk factor for ischemia and vascular dementia 6, and there is 
an association between  WMH and cognitive impairment and dementia43.  The incidence 
of WMH in all groups of patients was not statistically different. We excluded from the 
study patients with severe vascular risk factors and recognized vascular diseases, but the 
possibility of mild vascular pathology can not be entirely ruled out.  
Hcy metabolism, genes and dementia 
Hcy plasma levels may also be influenced by genetic factors that determine a less 
efficient metabolism of Hcy. These include the following (figure 1): 1.excessive 
production of S-adenosyl homocysteine when levodopa is metabolized by COMT; 2. 
reduced  remethylation of Hcy due to exhaustion of the pool of methyl donors, as in 
folate and/or vitamin B12 deficiency states or in individuals with genetically determined 
inefficiency of MTR or MTHFR; 3.deficient transulphuration pathway which can be 
genetically determined or result from vitamin B6 deficiency. Thus, 
hyperhomocysteinemia can arise from the effect of several polymorphisms on genes 
involved in Hcy metabolism. In the general population, possession of the T allele in 
MTHFR c.C677T, the C allele in MTHFR c.A1298C, the A allele in MTR c.A2756G or 
the c.844ins68 allele in CBS all caused hyperhomocysteinemia. However, only the 
MTHFR c.C667T polymorphism has been studied in PD patients. The TT variant of this 
polymorphism has been associated with higher Hcy plasma levels in PD patients treated 
with levodopa12-14, 44, 45. Other studies have shown that this variant does not influence 
Hcy plasma levels in levodopa-treated PD patients10  or in patients not receiving 
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levodopa 13.  Considering a possible interaction between genetic variants and levodopa 
intake in Hcy levels, we performed an extensive genetic assessment in this study. Plasma 
levels of Hcy were independent of genetic variations for every one of the polymorphisms 
and no association was found between the different polymorphisms studied and the 
cognitive status in PD patients. Admittedly, it could be argued that the influence of 
levodopa on Hcy levels is so overt that it makes it unlikely that any influence of these 
polymorphisms could be observed. 
In conclusion, we studied a patient population representative of advanced PD, and failed 
to find any evidence indicating that high Hcy plasma levels are a risk factor for cognitive 
decline. No association between Hcy plasma levels or polymorphisms of genes 
implicated in its metabolisms and cognitive impairment or dementia was found in PD 
patients.  However, the putative role of high Hcy levels in PD dementia cannot be 
entirely discarded given the pivotal role of Hcy in cellular metabolism. A prospective, 
large scale study with unselected PD patients is required for definitive ascertainment.  
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Tables and figure legends: 
 
Table 1 General characteristics of patients and controls and plasma levels of 
Homocysteine and cofactors in its metabolism 
Table 2 . Summary of the scores on neuropsychological tests in every group and 
correlation of scores in the whole population of PD patients with Hcy plasma levels. 
Table 3. Plasmatic levels of homocysteine corresponding to the different variants of the 
genetic polymorphisms in PD patients. 
Table 4. Genotype distribution at the polymorphisms analyzed stratified by 
population. 
Figure 1. Diagram showing the effect of levodopa on the metabolism of 
homocysteine. Note: the reaction involving BHMT is absent in from the brain. 
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Table 1 General characteristics of the patients and controls and plasma levels of 
homocysteine and cofactors in its metabolism  
 Control(n=30) PD-CN (n=37) PD-MCI(n=22) PD-D(n=30) 
Age 68.48 ±  2.98 69.97 ± 6.5 70.23 ± 5.2 74.87 ± 6.15** 
Sex ( % male) 51.72 54.55 63.64 60.00 
Years Evol ----- 14.68 ±4.62 13.05 ±  3.69 14.73 ± 4.45 
Educ ( %Pri) 68.97 65.00 91.67 81.25 
UPDRS OFF ----- 41.88 ±9.54 43.75 ± 4.76 48.11 ± 7.16 
Hoehn and Yahr ----- 3.35 ± 0 .91 3.43 ± 0 .62 3.94 ± 0.52 
Depression (GDS) 4.4  3.3 6.53  5.02 9.41  5.17θ 12.13  4.73 * 
Ldopa(mg/day) ----- 786.11 ± 262.68 825.04± 331.16 811.32± 338.09
DA agonists (%)  66.66 63.63 56.66& 
Hcy (µmol/l) 8.55 ± 1.95*** 14.9 ±  4.7 15.1 ±4.3 15.4 ±5.4 
Vit B12 (pg/ml) ----- 400.1± 222.2 353.2 ±205.6 380.2 ±156.5 
Vit B6 (nmol/l) ----- 49.5 ± 31.6 65.7 ±56.0 49.7 ±63.3 
Folate (ng/ml) ----- 10.2 ± 5.6 11.6 ±6.5 10.4 ±4.6 
 
 
Educ ( %Pri): Educational level ( % of primary school)   
DA agonist (%) Percentage of patients taking dopamine agonists 
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** P <0.0001 vs control and PD-CN;  p=0.02 vs PD-MCI 
* P <0.001 vs PD-CN  
θ p= 0.04 vs PD-CN 
& p= 0.04 vs PD-CN  
 
*** P =0.0001 between groups  
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Table 2. Summary of the scores of the neuropsychological tests in every group and 
correlation of the scores in the whole population of PD patients with Hcy plasma 
levels. 
 
   
Test Cut-off 
scores 
Controls PD -CN PD-MCI PD-D Pearson 
Correlation 
coefficient 
(r) in PD 
patients 
MMSE* 24  
 
28.93 (1.28) 29.0 (2.25) 25.0 (5.50) 19.0 (5.0) -0.176 
IDDD >35 33 35 (2.31) 35.4(3.2) 54.8 (14)  
Digit span 10 10.32 (2.11) 12.57 (3.27) 8.38 (3.58) 6.14 (3.08) -0.056 
Figure copy* 8 10. 0 (0.0) 10.0 (0.0) 10.0 (0.0) 8.0 (4.0) 0.032 
Figure recall* 6 6.48 (4.0) 8.0 (4.0) 2.0 (10.0) 0.0 (0.5) 0.051 
Phonemic fluency 10 13.86 (5.60) 13.79 (6.34) 10.13 (6.47) 7.43 (3.55) -0.060 
Semantic fluency 15 18.07 (4.83) 18.64 (4.75) 10.50 (2.72) 8.0 (3.11) -0.021 
FCSRT*  44 47.41 (0.8) 48.0 (1.0) 47.0 (7.75) 28.29 (24) -0.136 
Boston* 49 49.21 (5.52) 53.50 (6.25) 40.5 (14.25) 30.0 (5) 0.015 
Raven 26 26.93 (3.67) 26.0 (3.68) 17.75 (6.25) 13.57 (3.73) 0.038 
Trail A  70 sec 
(60-69 y.o) 
 100 sec 
(70-79 y.o)  
65.69 (29.42) 56.0 (24.10) 115.75(47.36) 233.58 (77.35) 0.114 
Trail B* 170 sec 
(60-69 y.o) 
 280 sec 
(70-79 y.o) 
137.31 
(55.63) 
140.0 (145) 245.0 (125.0) 301.0 (0.50) -0.064 
Stroop words 40 48.37 (6.27) 40.79 (11.01) 31.0 (8.70) 29.29 (6.16) -0.102 
Stroop color-word 40 43.93 (6.03) 43.78 (8.65) 37.92 (6.68) 28.56 (13.5) -0.154 
Mean and standard deviation, except tests with *, where median and interquartile range is 
shown. FCSRT (Free and cued selective reminding test). 
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Table 3. Plasmatic levels of homocysteine corresponding to the different variants of 
the genetic polymorphisms in PD patients. 
 
GENE VARIANT Hcy  *p-value 
 
MTHFRC677T 
CC (n=33) 15.75  4.19 reference 
CT (n=41) 14.45  5.50 
0.255 
TT (n=3) 13.76  3.80 
MTHFRA1298C 
AA (n=33) 15.07  4.69 reference 
AC (n=39) 14.59  5.32 0.336 
CC (n=10) 16.06  3.47 0.181 
MTRA2756G 
AA (n=59) 15.53  5.01 reference 
AG (n=21) 13.79  4.27 
0.152 
GG (n=2) 10.49  0.55 
CBS 844ins68 
I/I (n=68) 14.84  4.95 reference 
I/D (n=11) 14.19  3.12 
0.299 
D/D (n=3) 20.44  5.76 
 
*p value for the polymorphism included in the multiple regression model adjusted for 
age, Vit B12, Vit B6 and folic acid.  
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Table 4. Genotype distribution at the polymorphisms analyzed stratified by population. 
Gene 
cDNA 
(Protein) 
Control group Whole PD group (%) 
Cognitive normal PD 
(%) 
PD-MCI (%) PD-D(%) 
MTHFR C677T C/C C/T T/T C/C C/T T/T C/C C/T T/T C/C C/T T/T C/C C/T T/T 
 (A222V) 9 
(32.1) 
13 
(46.5) 
6 
(21.4) 
33 
(42.9) 
41 
(53.2) 
3 
(3.9) 
19 
(55.9) 
12 
(35.3) 
3 
(8.8) 
5 
(23.8)
16 
(76.2) 
0 
(0.0) 
9 
(40.9) 
13 
(59.1) 
0 
(0.0) 
 p 0.0239*                 0.080&  
                 
 A1298C A/A A/C C/C A/A A/C C/C A/A A/C C/C A/A A/C C/C A/A A/C C/C 
 (E429A) 15 
(57.7) 
9 
(34.6) 
2 
(7.7) 
33 
(40.2) 
39 
(47.6) 
10 
(12.2) 
13 
(36.1) 
19 
(52.8) 
4 
(11.1)
10 
(45.5)
10 
(45.5) 
2 
(9.0) 
10 
(41.7) 
10 
(41.7) 
4 
(16.6) 
 p 0.3277*                                                        0.901& 
                 
MTR A2756G A/A A/G G/G A/A A/G G/G A/A A/G G/G A/A A/G G/G A/A A/G G/G 
 (D919G) 19 9 1 59 21 2 20 14 2 20 2 0 19 5 0 
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(65.6) (31.0) (3.4) (72.0) (25.6) (2.4) (55.6) (38.9) (5.6) (90.9) (9.1) (0.0) (79.2) (20.8) (0.0) 
 p 0.6580*                                                       0.021& 
                 
CBS 844ins68 I/I I/D D/D I/I I/D D/D I/I I/D D/D I/I I/D D/D I/I I/D D/D 
  26 
(89.7) 
3 
(10.3) 
0 
(0.0) 
68 
(82.9) 
11 
(13.4) 
3 
(91.6) 
33 
(5.6) 
2 
(2.8) 
1 
(4.5) 
18 
(81.8)
3 
(13.6) 
1 
(4.5) 
17 
(70.8) 
6 
(25.0) 
1 
(4.2) 
 p 0.6437*                                                       0.141& 
 
*: P-values obtained comparing the genotype distribution at each SNP between cases and controls. All analysis was 
performed with 2 degrees of freedom. Corrected α value due to multiple comparisons: 0.0125  
& p-values obtained comparing the different groups of PD patients. Likelihood-ratio test p-value when the genetic 
polymorphism is added to the model adjusted for age. Corrected α value due to multiple comparisons: 0.0125 
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Figure 1. Diagram showing the effect of levodopa on the metabolism of homocysteine. 
Note: the reaction involving BHMT is absent in from the brain 
 
 
